

Matthew G Krebs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1216342/publications.pdf>

Version: 2024-02-01

24
papers

3,560
citations

516215

16
h-index

676716

22
g-index

24
all docs

24
docs citations

24
times ranked

5547
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. <i>Nature Medicine</i> , 2014, 20, 897-903.	15.2	608
2	Molecular analysis of circulating tumour cellsâ€™ biology and biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 129-144.	12.5	535
3	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. <i>Journal of Thoracic Oncology</i> , 2012, 7, 306-315.	0.5	411
4	Amivantamab in EGFR Exon 20 Insertionâ€™ Mutated Nonâ€™ Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	0.8	320
5	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€™2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	5.1	303
6	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1155-1164.	5.1	274
7	Circulating tumour cells: their utility in cancer management and predicting outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 351-365.	1.4	224
8	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. <i>Nature Medicine</i> , 2019, 25, 738-743.	15.2	202
9	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193
10	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. <i>Nature Cancer</i> , 2020, 1, 437-451.	5.7	103
11	Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. <i>Analyst</i> , The, 2016, 141, 669-678.	1.7	95
12	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusionâ€™ Positive Nonâ€™ Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	0.8	74
13	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 5213-5224.	3.2	53
14	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1156-1169.	1.1	47
15	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 115-122.e2.	1.0	43
16	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6284-6294.	3.2	24
17	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 61-66.	0.9	15
18	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusionâ€™ Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100332.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1271-1282.	0.6	12
20	Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 2443.	1.7	4
21	Abstract CT198: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study. <i>Cancer Research</i> , 2022, 82, CT198-CT198.	0.4	3
22	Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3150-TPS3150.	0.8	2
23	Differential response rates in early-phase cancer clinical trials (EPCCT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3133-3133.	0.8	0
24	Abstract 2975: RAS precision medicine transatlantic partnership: Exploration of RAS and NF1 co-mutations in NSCLC. <i>Cancer Research</i> , 2022, 82, 2975-2975.	0.4	0